https://www.selleckchem.com/pr....oducts/abemaciclib.h
In silico ADMET models have progressed significantly over the past ~4 decades but still the pharmaceutical industry is vexed by the late-stage toxicity failure of lead molecules. This problem of late-stage attrition of the drug candidates because of adverse ADMET profile motivated us to analyze the current role and status of different in silico tools along with the rise of machine learning (ML) based program for ADMET prediction. In this review, we have differentiated AI from traditional in silico tools because, unlike traditional i